Treatment of GERD
Proton pump inhibitors (PPIs) are the most effective first-line treatment for GERD, superior to H2-receptor antagonists (H2RAs) and placebo for both healing esophagitis and achieving symptomatic relief 1.
Initial Pharmacologic Management
Start with once-daily PPI therapy for 4-8 weeks as empirical treatment for patients with typical reflux symptoms (heartburn, acid regurgitation) without alarm features 2. This approach is strongly recommended (Grade A evidence) and appropriate for initial management of uncomplicated heartburn 1.
Dose Escalation Algorithm
If symptoms persist after 4-8 weeks on standard-dose PPI:
- Assess compliance first - many treatment failures are due to poor adherence or incorrect timing
- Escalate to twice-daily PPI dosing if once-daily therapy is inadequate 1. While most clinical trial data supports once-daily dosing, expert consensus unanimously recommends twice-daily dosing for refractory symptoms based on pharmacodynamic principles
- Consider patients treatment failures if symptoms persist despite twice-daily PPI - this represents the upper limit of empirical therapy and warrants further investigation 1
Do NOT add nighttime H2RAs to twice-daily PPI therapy - there is no evidence this improves efficacy 1.
Lifestyle Modifications: Targeted, Not Universal
The evidence does NOT support broadly recommending all lifestyle changes to every GERD patient (Grade Insufficient) 1. Instead, tailor modifications to individual patient circumstances:
Grade B Recommendations (Fair Evidence):
- Weight loss for overweight/obese patients - this may prevent or postpone the need for acid suppression 1
- Head-of-bed elevation - specifically for patients with nighttime heartburn or regurgitation that disturbs sleep, even despite acid suppressive therapy 1
Individualized Recommendations:
- Avoid specific trigger foods only if the patient consistently experiences heartburn after consuming them (e.g., alcohol, coffee, chocolate, fatty foods, citrus, carbonated drinks, spicy foods) 1
- Avoid late meals and recumbency for 2-3 hours after eating - for patients with postprandial symptoms 1
The problem with universal lifestyle recommendations is that each applies too narrowly to enforce the entire set on every patient 1.
Long-Term Maintenance Therapy
For Erosive Esophagitis:
Continuous daily PPI therapy is strongly recommended (Grade A) to maintain healed mucosa 1. Patients not maintained on continuous acid suppression have high recurrence rates of erosive disease.
- Do NOT use less-than-daily dosing (Grade D recommendation) in patients with previous erosive esophagitis - on-demand therapy results in high recurrence rates 1
- Titrate to the lowest effective dose based on symptom control, but maintain daily dosing 1
For Non-Erosive Reflux Disease (NERD):
On-demand PPI therapy is reasonable when symptom control is the primary objective (Grade B) 1. These patients tolerate intermittent dosing better than those with erosive disease.
The decision for maintenance therapy is driven by impact on quality of life rather than disease control, as there is no high-quality evidence that continuous therapy alters the natural history of reflux disease beyond reducing peptic stricture incidence 1.
Adjunctive Pharmacotherapy: Phenotype-Specific
Personalize adjunctive agents to the GERD phenotype rather than using them empirically 2:
- Alginate antacids - for breakthrough symptoms
- Nighttime H2RAs - for isolated nocturnal symptoms (not as add-on to twice-daily PPI)
- Baclofen - for regurgitation or belch-predominant symptoms
- Prokinetics - only for coexistent gastroparesis
Avoid metoclopramide as monotherapy or adjunctive therapy (Grade D - harms outweigh benefits) 1.
When to Perform Endoscopy
Perform endoscopy (Grade B) in:
- Patients with troublesome dysphagia (with biopsies for eosinophilic esophagitis if no visual abnormalities) 1
- Patients who have not responded to empirical twice-daily PPI trial 1
Surgical and Endoscopic Options
For carefully selected patients with proven GERD (confirmed by objective testing):
- Laparoscopic fundoplication - effective surgical option 2
- Magnetic sphincter augmentation - effective surgical option 2
- Transoral incisionless fundoplication (TIF) - effective endoscopic option 2
Candidacy requires confirmatory evidence of pathologic GERD, exclusion of achalasia, and assessment of esophageal peristaltic function 2.
Critical Pitfalls to Avoid
- Don't continue escalating PPI doses indefinitely - twice-daily is the upper limit; beyond this, investigate for alternative diagnoses 1
- Don't use on-demand therapy in patients with healed erosive esophagitis - they need continuous daily therapy 1
- Don't perform routine endoscopic surveillance in chronic GERD patients - monitoring has not been shown to diminish cancer risk 1
- Don't use metoclopramide - evidence shows it's ineffective with potential harms 1
The main risk of reducing or discontinuing PPI therapy is increased symptom burden, not progression to serious complications in most patients 1. This allows for pragmatic, patient-centered decisions about long-term therapy based on quality of life considerations.